About Annoviant
Founded in 2018, Annoviant is a cardiovascular device company developing next-generation regenerative implants that improve durability, reduce complications, and promote natural tissue remodeling.
The company is backed by leading healthcare institutions, research organizations, established vendors, incubator programs, FDA-funded consortia, NIH grants, and private capital.
The Clinical Challenge
Bluegrass Pharmaceuticals is a discovery-stage biotech company dedicated to advancing the next generation of Lipid Nanoparticles for superior vaccination efficacy.
While vaccines remain a cornerstone of modern medicine, innovation in protein-based vaccines—which represent over 50% of all vaccines administered—has lagged behind the recent mRNA surge. Current protein-based vaccines rely on aluminum salts (a technology dating back to the 1930s) to boost immune response, yet many still require multiple doses for lasting protection.
Myosin Therapeutics is a clinical and R&D-stage biotech C-corp incorporated in Delaware and based in South Florida.
The company’s innovative science was developed collaboratively in the labs of Drs. Miller, Griffin, and Kamenecka at the Department of Molecular Medicine, Wertheim UF Scripps Institute for Biomedical Innovation & Technology—a University of Florida research institute dedicated to new treatments.
Nemea Therapeutics is advancing first-in-class oral small molecule therapies that inhibit mitochondrial sustenance to treat aggressive solid tumors.
The lead program targets mitochondrial RNA polymerase (POLRMT)—a long-elusive cancer hallmark. Many advanced cancers increase reliance on mitochondrial function after standard chemotherapy, making POLRMT inhibition a promising approach for safer, more effective therapy across a broad range of malignancies.
PHIOGEN is a pre-clinical-stage biotechnology company developing first-in-class immunizing therapeutics designed to both treat drug-resistant infections and induce durable immune protection against recurrence, with a focus on chronic conditions.
Avast Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing first-in-class, non-invasive peptide therapeutics to treat neurodegenerative diseases, including Parkinson’s and Alzheimer’s.
Founded by University of Kentucky neuroscientists, Avast holds an exclusive license to a proprietary collection of small peptides capable of:
Kifa Therapeutics is a precision-neurology company developing first-in-class, mutant-selective kinase inhibitors to halt Parkinson’s disease at its genetic source.
Our lead program targets the G2019S mutation in LRRK2—the most common genetic cause of Parkinson’s—which drives neuronal toxicity through hyperactivation of the LRRK2 kinase pathway.
Nutrivert, based in Atlanta, is a preclinical-stage biotechnology company with worldwide exclusive patent rights to a breakthrough inflammation-sparing NOD2 agonist platform.
For 75 years, broad-spectrum antibiotics have transformed bacterial infections. Viral diseases deserve the same breakthrough: a simple prophylactic that prevents symptoms from common colds to pandemic threats like flu or coronavirus.
30 million Americans suffer from food allergies, with 6 million affected by peanut allergy—a life-threatening condition with no robust, disease-modifying treatments widely adopted.
Current management relies on strict avoidance and emergency epinephrine, leaving patients and families in constant fear of accidental exposure.
